 |
|
|
|
|
Checkpoint Signaling and DNA Repair: BRCA2
 | | |  BRCA2 Antibodies
|
|
|
|
|
| Anti-BRCA2 (Ab-1) Mouse mAb (2B) |
IB, IP |
human |
OP95 |
| Anti-BRCA2 (Ab-2) (3245-3418) Rabbit pAb |
IB, PS |
human |
PC146 |
| Anti-BRCA2 (Ab-2) Rabbit pAb |
IB, PS |
human |
PC146T |
|
| | | | Additional Information | | | | | | | | |
| Protein : BRCA2
| | |
|---|
| Connectivity | 102 |
|---|
| Notes | Mutations in BRCA1 and BRCA2 have been linked to an elevated risk of young onset breast cancer which has been demonstrated to be due to the inheritance of dominant susceptibility genes conferring a high risk of the disease. Unlike BRCA1, BRCA2 has not been linked to ovarian cancer. While BRCA1 mutations are typically microinsertions and point mutations, BRCA2 mutations are typically microdeletions. BRCA2 putatively functions as a tumor suppressor gene, however, its exact function has not been well characterized. The similarity of, and functional analysis of, BRCA2 and BRCA1 proteins, suggests that these proteins function in the same genetic pathway. BRCA1 and BRCA2 have transcriptional activation potential and the two proteins are associated with the activation of double-strand break repair and/or homologous recombination. The two proteins have been shown to coexist and colocalize in a biochemical complex. |
|---|
| Hugo ID | 1101 |
|---|
| Name | BRCA2 |
|---|
| Description | breast cancer 2, early onset |
|---|
| URN | urn:agi-llid:675 |
|---|
| | |
|---|
| GO Cellular Component | cytoplasm |
|---|
| | nucleus |
|---|
| | extracellular space |
|---|
| | secretory granule |
|---|
| | |
|---|
| Cell Localization | Nucleus |
|---|
| | Cytoplasm |
|---|
| | |
|---|
| GO Biological Process | DNA recombination |
|---|
| | response to DNA damage stimulus |
|---|
| | DNA repair |
|---|
| | chromatin remodeling |
|---|
| | double-strand break repair via homologous recombination |
|---|
| | establishment and/or maintenance of chromatin architecture |
|---|
| | mitotic checkpoint |
|---|
| | regulation of S phase of mitotic cell cycle |
|---|
| | regulation of cell cycle |
|---|
| | regulation of transcription |
|---|
| | |
|---|
| Alias | Brca2 |
|---|
| | breast cancer 2 |
|---|
| | RAB163 |
|---|
| | AW045498 |
|---|
| | expressed sequence AW045498 |
|---|
| | FAD1 |
|---|
| | FANCD1 |
|---|
| | BRC2 |
|---|
| | breast cancer 2, early onset |
|---|
| | Fanconi anemia, complementation group D1 |
|---|
| | BRC2_HUMAN |
|---|
| | BRCA2 protein |
|---|
| | breast cancer II |
|---|
| | Breast cancer type 2 susceptibility protein |
|---|
| | FAD I |
|---|
| | FANCD I |
|---|
| | Fanconi anemia, complementing group D1 |
|---|
| | HGNC:3585 |
|---|
| | |
|---|
| Organism | Rattus norvegicus |
|---|
| | Mus musculus |
|---|
| | Human |
|---|
| | |
|---|
| Group | protein binding |
|---|
| | nucleic acid binding |
|---|
|
|
 |
|
|
